Twitter Thread by Raghav Chaudhary



Raghav Chaudhary
@MrRChaudhary

#LAURUSLABS - CONCALL SNIPPET !

SHALL I CALL IT "EVERYONE'S FAVORITE" IN PHARMA SPACE!

(Only For Educational Purpose)

#Q1FY22 30 July

Laurus Labs

MrRChaudhary

Overview

- Laurus Labs is led by qualified and experienced promoters and efficient managerial personnel, who have extensive knowledge and insight of the global generic pharmaceutical business environment.
- The company operates in three business lines — Generics APIs, Generics Finished Dosage Forms (FDFs) and Synthesis/Ingredients.
- The company is engaged into manufacturing of APIs for Anti-Retroviral (ARVs), Oncology, Cardiovascular, Anti-Diabetics, Anti-Asthma, and Gastroenterology.
- Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.
- Company develops and manufacture oral solid formulations, provide Contract Research and Manufacturing Services (CRAMS) and Contract Development and Manufacturing Organization (CDMO) to global pharmaceutical companies.
- Company has six manufacturing facilities in Visakhapatnam and a kilo lab facility in Hyderabad, which have received approvals from WHO, US FDA, PMDA, NIP Hungary, KFDA, ANVISA, JAZMP – Slovenia, EU (Germany), COFEPRIS and BfArM.
- Laurus employs 4800+ people, including around 750+ scientists at more than 8 facilities approved by major regulatory agencies USFDA, WHO-Geneva, UK-MHRA etc. and in FY2021 generated over Rs4,800 crore in annual revenue.